---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-007772"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:09:27.515190+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Matinas reports positive MAT2203 compassionate use data: 12 of 15 patients improved, all completers resolved.

## Summary
- 19 patients enrolled in compassionate-use program for oral antifungal MAT2203; 15 evaluable.
- 12 of 15 patients had complete clinical resolution or objective improvement in infection markers.
- All 5 patients who completed full treatment (2 weeks to 1 year) had complete resolution with no relapse.
- All patients who transitioned from AmBisome due to renal toxicity saw return to baseline renal function.
- Patients treated at 9 major institutions including Johns Hopkins, NIH, Memorial Sloan Kettering.

## SEC filing metadata
- accession: 0001493152-24-007772
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224007772/0001493152-24-007772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224007772/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-007772
- JSON: https://secwatch.observer/filing/0001493152-24-007772.json
- Plain text: https://secwatch.observer/filing/0001493152-24-007772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.